The IU/JAX Alzheimer's Disease Precision Models Center: PTC Supplement

IU/JAX 阿尔茨海默病精确模型中心：PTC 补充资料

• 批准号: 9491281
• 负责人: Gregory W Carter
• 金额: $ 14.01万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-09-30 至 2021-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9491281
• 关键词: Academic Medical Centers; Alleles; Alzheimer disease prevention; Alzheimer' s Disease; Alzheimer' s disease model; Animal Disease Models; Animal Model; Animals; Area; Behavior; Biochemistry; Biological; Biological Markers; Biological Process; Biology; Blood Vessels; Cause of Death; Cessation of life; Clinic; Clinical; Clinical Trials; Clustered Regularly Interspaced Short Palindromic Repeats; Communities; Complex; Computer Simulation; Data; Data Set; Databases; Dementia; Development; Disease; Disease model; Drug Industry; Early Diagnosis; Effectiveness; Elderly; Ensure; Etiology; Failure; Functional disorder; Funding; Generations; Genes; Genetic; Genetic Models; Genome engineering; Genomic approach; Genomics; Goals; Growth; Heterogeneity; Human; Human Genetics; Image; Indiana; Informatics; Institution; International; Intervention; Laboratories; Late Onset Alzheimer Disease; Liquid substance; Mammalian Genetics; Medical; Medicine; Modeling; Mus; Nerve Degeneration; Outcome; Outcome Measure; Pharmacology; Phenotype; Preclinical Testing; Presenile Alzheimer Dementia; Prevalence; Process; Psychology; Research; Research Infrastructure; Resources; Sampling; Scientist; Systems Biology; Testing; The Jackson Laboratory; Therapeutic; Translations; United States; United States National Institutes of Health; Universities; Variant; amyloid precursor protein processing; animal imaging; cholesterol trafficking; clinically relevant; cost; data resource; disability; disease phenotype; drug testing; effective therapy; gene interaction; genetic technology; genome editing; genome sequencing; genome wide association study; human disease; imaging biomarker; innovation; insight; mouse genome; mouse model; multidisciplinary; neuroimaging; neuroinflammation; neuropathology; next generation; novel; novel therapeutics; pre-clinical; preclinical study; prevent; repository; symposium; synergism; web portal

PROJECT SUMMARY OVERALL COMPONENT Alzheimer's disease (AD) is a major cause of dementia, disability and death in the elderly. Despite recent advances in our understanding of basic biological mechanisms underlying AD, we do not yet know how to prevent AD or have an approved disease modifying intervention. Both are essential to slow or stop the growth in dementia prevalence. The National Alzheimer's Project Act (NAPA) seeks to prevent and effectively treat AD by 2025 through innovative research on etiology, early detection, and therapeutics. In support of NAPA's goals, one of the targeted areas of research identified at the NIA sponsored 2015 Alzheimer's Disease Research Summit was the development of the next generation of animal models of AD that will prove more predictive in preclinical studies and thus accelerate the drug testing pipeline. While our current animal models of AD have provided multiple novel insights into AD disease mechanisms, thus far they have not been successfully utilized to predict the effectiveness of therapies that have moved into AD clinical trials. The Indiana University (IU)/Jackson Laboratory (JAX) Alzheimer's Disease Precision Models Center (IU/JAX ADPMC) will leverage IU's strengths in neurodegenerative research including 25 years as an NIA-supported Alzheimer's Disease Center (ADC) and considerable expertise in preclinical drug testing with JAX's eight decades of expertise in mammalian genetics and disease modeling to develop, validate and disseminate new, precise animal models of Alzheimer's disease (AD). In addition, the IU/JAX ADMPC contains Sage Bionetworks to provide expertise in data organization and dissemination. The IU/JAX ADPMC brings together an international, multi-disciplinary team—including geneticists and genetics technology experts, quantitative and computational biologists, clinical experts in AD and neuroimaging, pharmacologists and world leaders in the development of precision animal models of disease—that possesses the collective ability to foresee disease modeling needs as they emerge on the international stage. This will allow the IU/JAX ADPMC to serve the AD scientific community effectively and efficiently. The IU/JAX ADPMC will generate new AD modeling processes and pipelines, data resources, research results and models that will be swiftly shared through JAX's and Sage's proven dissemination pipelines and through the NIA- supported AD Centers, academic medical centers, research institutions and the pharmaceutical industry worldwide. Ultimately, this will accelerate the application of advances in animal models for the greatest possible medical benefit. The Specific Aims of the IU/JAX ADPMC are: 1. Maximize Human Datasets to Identify Putative Variants, Genes and Biomarkers for AD. 2. Generate and Characterize the Next Generation of Mouse Models of AD. 3. Validate the Next Generation of Mouse Models of AD and Develop a Preclinical Testing Pipeline. !

项目总结性